Total Synthesis of (−)-Rhazinilam and Formal Synthesis of (+)-Eburenine and (+)-Aspidospermidine: Asymmetric Cu-Catalyzed Propargylic Substitution

Andrej Shemet and Erick M. Carreira*

ETH Zürich, Vladimir-Prelog-Weg 3, 8093 Zürich, Switzerland *Supporting Information Placeholder*

ABSTRACT: A total synthesis of (−)-rhazinilam and formal syntheses of (+)-eburenine and (+)-aspidospermidine are now reported which rely on a copper(I)-catalyzed asymmetric propargylic substitution as the key step. A salient feature of the reaction is the asymmetric construction of a quaternary stereocenter in high yield and enantiomeric excess.

The monoterpene indole alkaloid (−)-rhazinilam (**1**) was originally isolated from plant species *Rhazya stricta*, which grows wild in the desert regions of Iraq, Saudi Arabia, and the Yemen, as well as northwestern regions of the Indian subcontinent.^[1] Biological studies of 1 revealed cytotoxic activity towards various cancer cell lines at low micromolar range *in vitro,* [2] where it was shown to inhibit microtubule assembly and disassembly, as well as the formation of abnormal tubulin spirals.^[3-4] Accordingly, (-)-rhazinilam (**1**) has been recognized as a lead compound for the development of new antitumor agents. Structurally, this natural product contains a nine-membered lactam fused to a 5,6,7,8-tetrahydroindolizine possessing a quaternary stereocenter.

The unique structure of rhazinilam (**1**), coupled with its potent biological activity sparked interest within the synthetic community. In the early 1970`s, Smith and co-workers disclosed the first total synthesis of (±)-rhazinilam.[5a] To date, various approaches towards the synthesis of rhazinilam (**1**) have been reported in the literature.^[5-7] Within these approaches, the stereocontrolled formation of the quaternary center has typically represented a key challenge.^[6,8] Complex structures such as these compel researchers to develop novel strategies and methods for their construction. In previous asymmetric syntheses of

(−)-rhazinilam, the stereoselective formation of the quaternary center was achieved by nucleophilic attack of a pyrrole on various electrophilic sites (Figure 1A). Nelson and co-workers reported a Au(I)-catalyzed addition of pyrrole to an enantioriched allene,^[6b] and Banwell and co-workers employed chiral amine organocatalysis to effect conjugate addition of a pyrrole.^[6c] Herein, we report the development of an intramolecular Cu-catalyzed asymmetric propargylation using a pyrrole as C-nucleophile, and its application to the total synthesis of (−)-rhazinilam (**1**) and formal syntheses of (+)-eburenine (**8**) and (+)-aspidospermidine (**9**) (Figure 1B).

Figure 1. Structure and Syntheses of (−)-rhazinilam (1)

Recently, asymmetric Cu-catalyzed substitution reactions of racemic propargyl alcohol derivatives have attracted considerable attention (Scheme 1).^[9] Several classes of nucleophiles including alcohols, amines, and sulfides have been used to efficiently generate propargylic stereocenters with high levels of enantioselectivity.^[10] These reactions exploit the ability of copper acetylides **A**, generated from terminal propargylic alcohol derivatives, to form copper-allenylidenes **B** which are electrophilic at the γ-carbon to the copper center. Indeed, modifying copper with chiral ligands renders the subsequent γ-attack enantioselective, thus generating the corresponding optically active substitution products. Success has also been found using C-nucleophiles, yet the extension of this class of nucleophiles to substrates leading to quaternary centers still remains limited. The sole report was by Nishibayashi in 2016 wherein an intermolecular asymmetric Cu-catalyzed indole propargylation was developed using racemic tertiary trifluoromethylated propargylic esters.[11]

Scheme 1. Copper-catalyzed propargylic substitution

We saw the chemistry of copper allenylidenes as an opportunity to design a synthetic approach to (−)-rhazinilam, which centers on a novel intramolecular Cu-catalyzed propargylation of a pyrrole as the asymmetry-generating step in the route (Figure 1B). This strategy would allow for the highly efficient construction of the 5,6,7,8-tetrahydroindolizine core, while preserving an alkyne as a useful functional group handle.

Cyclization precursor **6** was easily synthesized in 4 steps from known pyrrole **12** as shown in Scheme 2. [12] With **6** in hand, we began screening reaction conditions for the planned Cu-catalyzed asymmetric propargylation substitution.

Initially, the combination of $(CuOTf)_2$ ·C₆H₆ and a series of PyBOX ligands, which were previously reported to effectively act as ligands in Cu-catalyzed enantioselective propargylic amination, were tested (Table 1). $^{[10a,b]}$ An initial solvent and base screening revealed that MeOH and Hünig's base was optimal. Furthermore, experiments employing **L1**-**L5** allowed desired bicyclic alkyne **7** to be obtained in high yield, yet only moderate levels of enantioselectivity were observed. In all cases, desired bicyclic alkyne **7** was formed in high yield but unfortunately in low enantioselectivity. Phenyl substituted oxazoline **L1** resulted in a moderate e.r. of 71:29 (Entry 4). Upon increasing the electron density of the ligand by methoxy-substitution of the aromatic ring, alkyne **7** was isolated in 83% yield and 76:24 e.r. (Entry 5). These promising results prompted us to further modify the substitution pattern of the oxazolines. Hence, naphthyl-substituted ligand **L3** and trimethoxy-substituted ligand **L5** were synthesized and tested. Slightly higher selectivity was achieved with ligand **L3** (Entry 6), and to our delight, alkyne **7** was isolated in 84% yield with 82:18 e.r. when L5 was employed (Entry 8). The use of different copper-source such as $[(CH₃CN)₄Cu]PF₆$ or [(CH₃CN)₄Cu]BF₄ provided slightly higher yields in the reactions (Entries 9-10). Importantly, we noted that the enantioselectivity of the reaction could be slightly improved by switching to 2,2,2-trifluorethanol

as solvent at −25 °C. Under these conditions, bicyclic alkyne **7** was obtained in 89% yield with 90:10 e.r. (Entry 12). It should be noted that the use of activating groups other than acetate, such as propargylic carbonates, did not lead to any further improvement of yield or e.r. The corresponding free propargylic alcohol did not show any reactivity under the optimized conditions, and led only to recovery of starting material.

Table 1. Optimization of reaction conditions

Reaction conditions: [Cu] (5-mol %), ligand (10-mol %), solvent (0.1 M) from -8 °C to 0 °C. (a) A: (CuOTf)2·C6H6; B: [(CH3CN)4Cu]PF6; C: [(CH3CN)4Cu]BF⁴ (b) isolated yield (c)−25 °C for 26 h; (d) **(***R***)-7** was obtained as major enantiomer. THF = tetrahydrofuran, TFE = 2,2,2-trifluoroethanol

With the optimized conditions in hand, our focus turned towards the completion of the synthesis of (−)-rhazinilam. As shown in Scheme 3, deprotonation of alkyne **7** and subsequent trapping with ethyl chloroformate, followed by hydrogenation using Adam's catalyst afforded ester **15** in 75% overall yield. To our surprise, the use of standard peptide coupling reagents to convert free acid to amide **16** failed due to the high nucleophilicity of the pyrrole and instead led to acylation of the C3-position of the pyrrole. However, the condensation of 15 with 2-iodoaniline could be effected in 97% yield by AlMe₃.

With this material in hand, we turned our attention towards formation of the nine-membered lactam **18**. In earlier syntheses, Trauner and co-workers demonstrated that the formation of similar macrocycles could be achieved by Pd-catalyzed biaryl coupling.[5d,13] In line with these reports, **16** was protected, giving **17** in 71% yield. However, Trauner`s conditions led to the desired product being isolated in only 10% yield. Extensive screening studies were necessary to achieve the formation of lactam **18** by palladium catalysis. The highest yield of 18 (38%) was obtained using catalytic Pd(OAc)₂ as well as K₂CO₃ and DMA as base and solvent, respectively. Furthermore, it was found that the addition of H_2O (10 equivalents) was crucial for this reaction to proceed, while the use of phosphine ligands to modify Pd had minimal effect on the reaction outcome. Deprotection occurred upon exposure to BCl₃ at −78°C in CH₂Cl₂, affording (−)-rhazinilam (**1**) in 6 steps from alkyne **7**. The spectroscopic data of the synthetic material matched those of the natural product. Comparison of the optical rotation between the synthetic material and the natural product enabled the configurational assignment of the copper-catalyzed transformation of propargylic ester **6** to indolizine **7**.

Scheme 3. Completion of the total synthesis of (−)-rhazinilam

(−)-Rhazinilam (**1**) has been recognized as the oxidative degradation product of (+)-eburenine (**8**) and shares a common central structural feature of aspidosperma alkaloids (Scheme 4).^[5a] In order to further exploit the novel Cu-catalyzed propargylic substitution we turned our attention towards the synthesis of (+)-aspidospermidine (9) (Scheme 5). Lithiation of alkyne 7 with *n*-BuLi and quenching with CO₂ afforded acid **19** in excellent yield (91%). Subsequent hydrogenation using Pd/C converted alkynoic acid **19** to its saturated analog **20**, which readily engaged in an intramolecular Friedel-Crafts acylation upon treatment with polyphosphoric acid to form tricyclic ketone 21. Reduction with PtO₂ and H₂, followed by treatment with DMP provided pyrrolidine **22** as single diastereomer in 25% yield over two steps. Tricycle **22** was also prepared by Banwell, yet this group was not successful in converting it to **9**. [14] However, we found that Fischer indolization could be used to obtain **8** in 53% yield. Reduction of indoline moiety gave (+) aspidospermidine (**9**) in 80% yield. Moreover, **8** can be converted to (+)-vincadifformine (**23**) and other related alkaloids via known procedures.^[15]

Scheme 4. Biosynthesis of (−)-rhazinilam

Scheme 5. Formal synthesis of (+)-eburenine, and (+)-aspidospermidine

PPA= Polyphosphoric acid

In summary, we have developed an efficient asymmetric copper-catalyzed intramolecular substitution of propargylic acetate with pyrrole to enable rapid and asymmetric access to 5,6,7,8-tetrahydroindolizines bearing an all-carbon quaternary stereocenter. The utility of this copper-catalyzed asymmetric propargylic substitution was exemplified by a concise total synthesis of (−)-rhazinilam (**1**). Additionally, formal syntheses of (+)-eburenine (**8**), (+)-aspidospermidine (**9**) were achieved from alkyne **7**, demonstrating the versatility of this approach. We are currently focusing on the expansion of this transformation in order to access other highly substituted propargylic products in an asymmetric fashion.

Corresponding Author

*E-mail: carreira@org.chem.ethz.ch

Notes

The authors declare no competing interest.

ACKNOWLEDGMENT

We are grateful to Dr. N. Trap (ETH Zürich) and M. Solar (ETH Zürich) for X-ray crystallographic analyses. We thank the Swiss National Science Foundation for support in the form of a grant: 200020_172516.

REFERENCES

- [1] (a) Linde, H.A. *Helv. Chim. Acta* **1965**, *48*, 1822. (b) Banerji, A.; Majumder, P.L.; Chatterjee, A. *Phytochemistry.* **1970**, *9*, 1491. (c) Abraham, D.J.; Rosenstein, R.D.; Lyon, R.L.; Fong, H.H.S. *Tetrahedron Lett.* **1972**, *13*, 909. (d) Omar, M.S. *Rhazya stricta* Decaisne: In vitro culture, and the production of indole alkaloids. In *Biotechnology in Agriculture and Forestry;* 1st edition; Bajaj, Y.P.S., Eds.; Springer-Verlag: Berlin, 1988, p 529.
- [2] Décor, A.; Bellocq, D.; Thoison, O.; Lekieffre, N.; Chiaroni, A.; Ouazzani, J.; Cresteil, T.; Guéritte, F.; Baudoin, O. *Bioorg. Med. Chem.* **2006,** *14*, 1558.
- [3] David, B.; Sévenet, T.; Morgat, M.; Guénard, D.; Moisand, A.; Tollon, Y.;Thoison, O.; Wright, M. *Cell Mot. Cytoskeleton* **1994**, *28*, 317.
- [4] Baudoin, O.; Guenard, D.; Gueritte, F. *Mini-Rev. Org. Chem.* **2004**, *1*, 333.
- [5] For total syntheses of (±)-rhazinilam, see: (a) Ratcliffe, A.H.; Smith, G.F.; Smith, G.N. *Tetrahedron Lett.* **1973**, *14*, 5179. (b) Johnson, J.A.; Sames, D. *J. Am. Chem. Soc.* **2000**, *122*, 6321. (c) Magnus, P.; Rainey, T. *Tetrahedron* **2001**, *57*, 8647. (d) Bowie, A.L.; Hughes, C.C.; Trauner D. *Org. Lett.* **2005**, *7*, 5207. (e) Banwell, M.G.; Edwards, A.J.; Jolliffe, K.A.; Smith, J.A.; Hamel, E.; Verdier-Pinard, P. *Org. Biomol. Chem.* **2003**, *1*, 296. (f) McMurray, L.; Beck, E.M.; Gaunt, M.J. *Angew. Chem., Int. Ed.* **2012**, *51*, 9288. (g) Su, Y.; Zhou, H.; Chen, J.; Xu, J.; Wu, X.; Lin, A.; Yao, H. *Org. Lett.* **2014**, *16*, 4884. (h) Yang, Y.; Bai, Y.; Sun, S.; Dai, M. *Org. Lett.* **2014**, *16*, 6216.
- [6] For asymmetric total syntheses of (−)-rhazinilam, see: (a) Johnson, J.A.; Li, N.; Sames, D. *J. Am. Chem. Soc.* **2002**, *124*, 6900. (b) Liu, Z.; Wasmuth, A.S.; Nelson, S.G. *J. Am. Chem. Soc.* **2006**, *128*, 10352. (c) Banwell, M.G.; Beck, D.A.S.; Willis, A.C. *ARKIVOC* **2006**, 163. (d) Gu, Z.; Zakarian, A. *Org. Lett.* **2010**, *12*, 4224. (e) Sugimoto, K.; Toyoshima, K.; Nonaka, S.; Kotaki, K.; Ueda, H.; Tokuyama, H. *Angew. Chem. Int. Ed.* **2013**, *52*, 7168. (f) Gualtierotti, J.-B.; Pasche, D.; Wang, Q.; Zhu, J. *Angew. Chem., Int. Ed.* **2014**, *53*, 9926. (g) Sugimoto, K.; Miyakawa, Y.; Tokuyama, H. *Tetrahedron* **2015**, *71,* 3619. (h) Dagoneau, D.; Xu, Z.; Wang, Q.; Zhu, J. *Angew. Chem. Int. Ed.* **2016**, *55*, 760. (i) Magné, V.; Lorton, C.; Marinetti, A.; Guinchard, X.; Voituriez, A. *Org. Lett.* **2017**, *19*, 4794.
- 7 For reviews, see: (a) Kholod, I.; Vallat, O.; Buciumas, A.-M.; Neier, R. *Heterocycles* **2011**, *82*, 917. (b) Crossley, S.W.M.; Shenvi, R. A. *Chem. Rev.* **2015**, *115*, 9465.
- [8] Quasdorf, K.W.; Overman, L.E. *Nature* **2014**, *516*, 181.
- [9] For reviews, see: (a) Nishibayashi, Y.; *Synthesis* **2012**, *44*, 489. (b) Detz, R.J.; Hiemstra, H.; van Maarseveen, J.H. *Eur. J. Org. Chem.* **2009**, *2009,* 6263. (c) Hu, X.-H.; Liu, Z.-T.; Shao, L.; Hu, X.-P. *Synthesis* **2015**, *47*, 913.
- 10 Selected example for copper-catalyzed enantioselective propargylic substitution reactions: (a) Detz, R.; Delville, M.M.E.; Hiemstra, H.; van Maarseveen, J.H. *Angew. Chem., Int. Ed.* **2008**, *47*, 3777. (b) Hattori, G.; Matsuzawa, H.; Miyake, Y.; Nishibayashi, Y. *Angew. Chem., Int. Ed.* **2008**, *47*, 3781. (c) Yoshida, A.; Ikeda, M.; Hattori, G.; Miyake, Y.; Nishibayashi, Y. *Org. Lett.* **2011,** *13,* 592. (d) Nakajima, K.; Shibata, M.; Nishibayashi, Y. *J. Am. Chem. Soc.* **2015**, *137*, 2472. (e) Huang, G.; Cheng, C.; Ge, L.; Guo, B.; Zhao, L.; Wu, X. *Org. Lett.* **2015**, *17*, 4894. (f) Liu, Z.-T.; Wang, Y.-H.; Zhu, F.-L.; Hu, X.-P. *Org. Lett.* **2016**, *18*, 1190.
- [11] Tsuchida, K.; Senda, Y.; Nakajima, K.; Nishibayashi, Y. *Angew. Chem., Int. Ed.* **2016**, *55*, 9728.
- [12] See supporting information.
- [13] Bowie, A.L.; Trauner, D. *J. Org. Chem.* **2009**, *74*, 1581.
- [14] (a) Banwell, M.G.; Smith, J.A. *J. Chem. Soc., Perkin Trans.1* **2002**, 2613. (b) Iyengar, R.; Schlidknegt, K.; Aubè, J. *Org. Lett.* **2000**, *2*, 1625.
- [15] Jones, S.B.; Simmons, B.; Mastracchio, A.; MacMillan, D.W.C. *Nature* **2011**, *475*, 183.